WA
HUMA icon

Waverly Advisors’s Humacyte HUMA Stock Holding History

Waverly Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.5K Buy
23,672
+846
+4% +$784 ﹤0.01% 1732
2026
Q1 		$13.8K Buy
22,826
+3,775
+20% +$3.92K ﹤0.01% 1600
2025
Q4 		$18.3K Sell
19,051
-247,990
-93% -$351K ﹤0.01% 1462
2025
Q3 		$465K Sell
267,041
-3,813
-1% -$7.47K ﹤0.01% 871
2025
Q2 		$566K Sell
270,854
-7,337
-3% -$14.1K 0.01% 765
2025
Q1 		$474K Buy
278,191
+3,612
+1% +$13.6K 0.01% 793
2024
Q4 		$1.39M Buy
274,579
+211,009
+332% +$1.04M 0.02% 458
2024
Q3 		$346K Buy
63,570
+52,738
+487% +$348K 0.01% 652
2024
Q2 		$52K Buy
10,832
+82
+0.8% +$427 ﹤0.01% 794
2024
Q1 		$33.4K Buy
+10,750
New +$36.1K ﹤0.01% 685

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Waverly Advisors's HUMA Position: Q2 2026 in Review

Waverly Advisors increased its Humacyte (HUMA) stake by 3.7% in Q2 2026, buying an estimated $784 and bringing the position to 23,672 shares worth $18.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1732.

Waverly Advisors first reported a position in HUMA in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.39M in Q4 2024. 163 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Waverly Advisors held 23,672 shares of Humacyte worth $18.5K as of Q2 2026.
  • Waverly Advisors bought 846 Humacyte shares in Q2 2026, an estimated $784.
  • Humacyte made up ﹤0.01% of Waverly Advisors's portfolio in Q2 2026, its #1732 holding.
  • Waverly Advisors first reported a position in Humacyte in Q1 2024 and has held it in 10 quarters since.
  • Waverly Advisors's Humacyte position peaked at $1.39M in Q4 2024.
  • 163 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Waverly Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.